Traders should monitor upcoming clinical data readouts and potential achievement of the third $10 million milestone later in 2026. The partnership with Novo Nordisk de-risks development and validates LX9851's potential, supporting upside in Lexicon's valuation despite its small market cap.
LXRX drugs
LXRX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 23 $1.64entry
- T+1 · 8mo ago +4.88%α +5.23% · $1.72
- T+5 · 8mo ago −7.93%α −4.36% · $1.51
- T+20 · 7mo ago +11.59%α +4.17% · $1.83
- T+60 · 5mo ago +24.39%α +11.33% · $2.04
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lexicon Pharmaceuticals announced that Novo Nordisk has initiated a Phase 1 clinical trial for LX9851, a first-in-class oral obesity candidate discovered by Lexicon. As a result, Lexicon earned a $10 million milestone payment and remains eligible for up to $1 billion in total milestones plus royalties on future sales.
Key Financial Metrics
Key Facts
- Novo Nordisk initiated a Phase 1 study of LX9851, triggering a $10 million milestone payment to Lexicon.
- Lexicon is eligible for up to $1 billion in total upfront and milestone payments, including a third $10 million milestone potentially this year.
- LX9851 is a novel oral non-incretin drug targeting obesity with preclinical data showing enhanced weight loss when combined with semaglutide.
- The Phase 1 trial will evaluate safety, tolerability, and pharmacokinetics in 96 individuals with overweight or obesity, with completion expected in Q1 2027.
Financial Impact
$10 million received in 2026, with potential for up to $1 billion in total milestones and tiered royalties on future sales
Risk Factors
- Future milestone payments and royalties depend on successful development and regulatory approval, which are uncertain.
- Competition in the obesity pharmacotherapy space is intensifying with GLP-1-based therapies dominating the market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260282 |
Track record
16 reports on LXRX
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +27.52% at T+20 after the Sep 22, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $2.18 to $2.06 Now $1.75 +19.72% ▲ +5.50% +4.78% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 No price data
- Aug 6, 202614w ago Press Release Neutral 5/10 Entry $2.36 to $2.47 Now $1.75 −25.85% ▲ +4.66% +4.05% vs SPY
- Jun 12, 202622w ago Institutional Cluster Bearish 5/10 Entry $1.92 to $1.96 Now $1.75 +8.85% ▼ −2.08% −0.32% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.89 to $1.92 Now $1.75 −7.41% ▲ +1.59% +1.05% vs SPY
- May 6, 202627w ago 8-K Neutral 4/10 Entry $1.68 to $1.68 Now $1.75 +4.17% · 0.00% −0.83% vs SPY
- Apr 30, 202628w ago 8-K Bearish 6/10 Entry $1.63 to $1.60 Now $1.75 −7.36% ▲ +1.84% +1.50% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers